PPMS patients taking Ocrevus are less likely to see progression
Having recently concluded an ORATORIO phase III clinical trial of primary progressive multiple sclerosis (PPMS) patients, Genentech’s Ocrevus (ocrelizumab) increased the number of patients found to have no experienced progression (NEP) when taking the drug...Read more - http://www.ms-uk.org/ppms-patients-taki ... ion-100317
PPMS patients taking Ocrevus are less likely to progress...
PPMS patients taking Ocrevus are less likely to progress...
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 2216 Views
-
Last post by NHE
-
- 0 Replies
- 1071 Views
-
Last post by NHE
-
- 0 Replies
- 10872 Views
-
Last post by NHE
-
- 0 Replies
- 2116 Views
-
Last post by Firidion
-
- 1 Replies
- 1364 Views
-
Last post by vesta
-
- 0 Replies
- 2106 Views
-
Last post by frodo
-
- 0 Replies
- 2027 Views
-
Last post by NHE
-
- 0 Replies
- 1527 Views
-
Last post by NHE
-
- 4 Replies
- 2538 Views
-
Last post by JohnC777